The Company has reported Q4 and full-year F2013 results, with revenue for F2013 up 14% compared with F2012. Microbix has provided updates on its thrombolytic drug Kinlytic™ (Urokinase) as well as announcing patent litigation against Novartis Vaccines and Diagnostics.
Read more in the Perspective here: Microbix Biosystems
eResearch is a primary source for professional investment research, focused on small- and mid-cap companies. Our research and analysis is of institutional quality, and has the potential for reaching millions of global investors through our extensive electronic distribution network.
eResearch posts all its reports and articles on its website, eresearch.ca, and subscription is FREE.
Contact:
eResearch: Bob Weir, CFA,
Director of Research
Telephone:
(416) 703-6258
email:
[email protected]